
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 25 years ago
Participating Facultyover 25 years ago
Introductionover 25 years ago
Evaluation of the Patient with Epilepsyover 25 years ago
Pharmacokinetics of the New Antiepileptic Drugsover 25 years ago
Treatment of Epilepsy in Three Specialized Populationsover 25 years ago
Roundtable Discussionover 25 years ago
Continuing Medical Education Quizover 25 years ago
Selected Abstracts





